Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
11 2020
Historique:
received: 23 04 2020
accepted: 05 09 2020
pubmed: 26 9 2020
medline: 10 4 2021
entrez: 25 9 2020
Statut: ppublish

Résumé

Minimal important differences (MIDs) are useful for interpreting changes or differences in health-related quality of life scores in terms of clinical importance. There are currently no MID guidelines for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) specific to ovarian cancer. This study aims to estimate MIDs for interpreting group-level change of EORTC QLQ-C30 scores in ovarian cancer. Data were derived from four EORTC published trials. Clinical anchors for each EORTC QLQ-C30 scale were selected using correlation strength and clinical plausibility. MIDs for within-group change and between-group differences in change over time were estimated via mean change method and linear regression respectively. For each EORTC QLQ-C30 scale, MID estimates from multiple anchors were summarized via weighted-correlation. Distribution-based MIDs were also examined as supportive evidence. Anchor-based MIDs were determined for deterioration in 7 of the 14 EORTC QLQ-C30 scales assessed, and in 11 scales for improvement. Anchor-based MIDs for within-group change ranged from 4 to 19 (improvement) and - 9 to -4 (deterioration). Between-group MIDs ranged from 3 to 13 (improvement) and - 11 to -4 (deterioration). Generally, absolute anchor-based MIDs for most scales ranged from 4 to 10 points. Our findings will aid interpretation of EORTC QLQ-C30 scores in ovarian cancer and inform sample size calculations in future ovarian cancer trials with endpoints that are based on EORTC QLQ-C30 scales.

Identifiants

pubmed: 32972782
pii: S0090-8258(20)33900-7
doi: 10.1016/j.ygyno.2020.09.007
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

515-521

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None declared.

Auteurs

Jammbe Z Musoro (JZ)

European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium. Electronic address: jammbe.musoro@eortc.org.

Corneel Coens (C)

European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.

Elfriede Greimel (E)

Medical University Graz, Graz, Austria.

Madeleine T King (MT)

University of Sydney, Faculty of Science, School of Psychology, Sydney, NSW, Australia.

Mirjam A G Sprangers (MAG)

Department of Medical Psychology, Amsterdam University Medical Centers, location Academic Medical Center, University of Amsterdam, Cancer Center Amsterdam, the Netherlands.

Andy Nordin (A)

East Kent Gynaecological Oncology Centre, Queen Elizabeth the Queen Mother Hospital, UK.

Eleonora B L van Dorst (EBL)

Department of Obstetrics and Gynecology, Academic Hospital Utrecht, Utrecht, the Netherlands.

Mogens Groenvold (M)

Department of Public Health, University of Copenhagen, and Bispebjerg Hospital, Copenhagen, Denmark.

Kim Cocks (K)

Adelphi Values, Bollington, Cheshire, UK.

Galina Velikova (G)

Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.

Hans-Henning Flechtner (HH)

Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Magdeburg, Magdeburg, Germany.

Andrew Bottomley (A)

European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH